REGENXBIO(RGNX) - 2024 Q1 - Quarterly Results

EXHIBIT 99.1 REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights • Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) • Dose level 2 selected as pivotal dose for RGX-202 treatment of Duchenne o New positive interim efficacy and safety data announced for second boy at DL2 o AFFINITY DUCHENNE® trial expansion phase is underway with third and fourth ...